Teva Pharmaceutical Industries Ltd (TEVA)
$9.84 0.00 (0.00%)
19:59 EDT TEVA Stock Quote Delayed 20 Minutes
Previous Close $9.84
Market Cap 10.02B
PE Ratio -0.62
Volume (Avg. Vol.)
Day's Range 9.84 - 9.84
52-Week Range 6.07 - 15.72
Dividend & Yield 0.07 (0.73%)
TEVA Stock Predictions, Articles, and Teva Pharmaceutical Industries Ltd News
- From InvestorPlace
- From the Web
As the coronavirus pandemic worsens, stable but boring recession-proof stocks to buy are suddenly in vogue. Here are the nine picks that might ride this black swan even to profitability.
By Thomas Niel
TEVA stock was a great contrarian play last fall. With opioid liabilities hanging like an anvil over the company, shares were priced for disaster. More than doubling from their 2019 lows, I wouldn't say Teva shares are now "priced to perfection". But, the current share price may be pricing in much of the upside. Bottom Line? Consider TEVA stock a hold. With markets facing volatility, a better entry point could spring up down the road.
The forward price-earnings ratio of Teva stock is only 5, and its trailing price/sales ratio is 0.8. With Teva's financial situation in control and given the company's multiple growth drivers, those valuation metrics are quite low.
TEVA stock is about as far from a feel-good investment as you can get. But the underlying generics drug industry is still an important one, making shares a tough contrarian opportunity.
Teva stock rose 9% after a positive earnings report. But after $3 billion in cost-cutting, investors may be looking for additional revenue.
Here's your complete guide on which stocks to buy, depending on who wins the 2020 U.S. Presidential Election.
It increasingly appears that Teva stock is in the early stages of going from multi-year loser to multi-year winner.
Teva Pharmaceuticals (TEVA) earnings for the pharmaceutical company's fourth quarter of 2019 have TEVA stock taking off on Wednesday.
With plans to capture 25% of the market, the nod from the FDA should help reduce the sting of having to abandon its planned use of Ajovy for cluster headaches, a move that was dropped last year after a failed phase 3 trial, which gave Eli Lilly the market to itself.
Teva Pharmaceuticals may look interesting after its recent surge, but the near-term outlook of TEVA stock is somewhat murky.
Teva can handle its debt and deal with its liability from the opioid tragedy. And Teva stock has multiple, positive catalysts.
Suffering from many missteps, generics drugmaker Teva is still struggling to heal. Here's what to expect from TEVA stock in 2020.
Teva stock has been a long-term loser, but there are signs that things are starting to turn around. Should investors consider it in 2020?
While Schulz's cost-cutting has reduced Teva's debt by more than $8 billion, more needs to be done to bolster the company's balance sheet.
Teva's debt restructuring gives it breathing room through 2021, assuming its legal woes don't get worse. Buy Teva stock at your own risk.
Lately, Teva stock has had a nice rally, but this may prove temporary. The fact is that the company faces much uncertainty with the litigation.
A portfolio should hold high-risk, high-reward plays. And these nine stocks to buy offer big risks and even bigger potential returns.
By Thomas Niel
With shares rebounded, now may not be the time to enter Teva stock. Wait to see how upcoming opioid trials play out. If shares pull back to prior price levels, a buying opportunity may emerge. But for now, the risks do not match up with potential upside.
From Seeking Alpha
Navellier RatingsPowered by Portfolio Grader